Experimental AI models deliver 90%-plus accuracy in COVID screening

Cross-Atlantic researchers have developed two AI models that are fast and accurate at screening for COVID-19, offering hospitals potential options when lab testing is backed up or unavailable.

The team, which includes members from Harvard and Oxford, has posted its results on the preprint server medRxiv prior to obtaining peer review.

If they come through that process, the models could let ER or admissions staff check for COVID using health-status data routinely collected upon patients’ arrival at hospital.

After using such data from more than 115,000 ER visits and more than 72,000 admissions to train the models, Andrew Soltan of Oxford and colleagues found their emergency model achieved 77.4% sensitivity and 95.7% specificity for COVID-19.

Their admissions model performed similarly—77.4% sensitivity and 94.8% specificity.

Both models brought back high negative predictive values (>99%) across a range of prevalences (<5%), “facilitating rapid exclusion during triage to guide infection control,” the authors report.

What’s more, prospective validation showed both models had accuracies north of 90% at a large U.K. teaching hospital over a two-week period.

“Our work demonstrates that an AI-driven screening test can effectively triage patients presenting to hospital for COVID-19 while confirmatory laboratory PCR (polymerase chain reaction) testing is awaited,” Soltan et al. conclude. “Our approach is rapidly scalable, fitting within the existing laboratory testing infrastructure and standard of care, and additionally serves as proof-of-concept for a rapidly deployable software tool in future pandemics.”

They call for prospective clinical trials to assess the models’ real-world performance and generalizability to other care settings.

Click here for the study abstract, and select “Preview PDF” to read the full preprint report. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.